TNF and uveitis: Adalimumab (ADA), a recombinant human immunoglobulin (IgG1) monoclonal antibody that specifically binds to TNF-α [2, 7, 8], is the only systemic noncorticosteroid agent currently approved for the treatment of noninfectious primary or secondary uveitis [9].